Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Oncology Trials Designed For “Learning On The Go”

Executive Summary

Roche is innovating in the structure of clinical development to manage the increasingly complex knowledge of cancer biology, using adaptive trial designs and extensive analysis of responders to find biomarkers that can inform, adjust and enrich clinical studies in a continually iterative process of “learning on the go.”

You may also be interested in...



Cancer Trial Endpoints: Minimal Residual Disease Eyed As Surrogate

More work needs to be done to validate MRD as predictive of clinical outcomes in hematological malignancies before it can be used as the basis for accelerated approval, FDA and other stakeholders say.

Big Pharma Explores New Frontier Of Lung Cancer Immunotherapy

Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.

Sponsors’ Use Of Adaptive Designs Appears To Be Growing

A Drug Information Association working group survey found 477 studies between Jan. 1, 2008 and Sept. 1, 2011 utilized some type of adaptive design.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel